These have included IGF-1, which resulted in improvements in weight gain and growth in diabetic rats, when used alone or in combination with insulin (55), sclerostin inhibition which lead to improvements in bone healing in a fracture model of insulin-deficient diabetes in mice by altering the Wnt pathway (56) and teriparatide and abaloparatide which increased bone mass and improved bone strength and bone turnover in mice with STZ-induced diabetes (57). Here, SOST is linked to diabetes mellitus.